Home Wealth  Money Gilead Pays Up For Pharmasset

Gilead Pays Up For Pharmasset

Posted: Nov. 22nd, 2011  |  By Forbes

powered by Forbes

RSS Syndicated News Email a Friend Suggest an Article Share Visit Website

Gilead Sciences has agreed to acquire Pharmasset for $137 per share in cash.

The transaction values Pharmasset (nasdaq: VRUS - news - people ) at $11 billion, and is expected to be completed in the first quarter of 2012.

Pharmasset's board has approved the transaction, and Gilead (nasdaq: GILD - news - people ) said it will be accretive to earnings beginning in 2015.

Gilead said the acquisition represents an important and exciting opportunity to accelerate its effort to change the treatment paradigm for hepatitis C with all-oral regimens.

Pharmasset has three clinical-stage candidates for the treatment of chronic hepatitis C virus.

Keep an eye on shares of Regeneron Pharmaceuticals (nasdaq: REGN - news - people ) today as well.

The company said late Friday the US Food and Drug Administration has approved its EYLEA injection for the treatment of patients with neovascular age-related macular degeneration.

The treatment was approved at a dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 milligrams every eight weeks.

Market News Video produces and distributes online videos about stocks and investing.

Share on Facebook Share
See Next Article
Need to Get Away?
Top 10 Business Hotels
Who says you can’t mix business with pleasure?
Read More
More Articles from Forbes.com

Quick Links
Real Estate
Luxury Travel
Search Real Estate
Find Your Dream Home
Search for homes by
State, Country or Style.
Event Calendar
Current News & Features
Dined at the Best Michelin Starred Restaurants in Asia Yet?
A Passion For Wine, Redefined
Olympic Star Torah Bright Drives Hard With Porsche
Get An Inside Look At Bang & Olufsen's Design Process
Understanding the History & Profiles of Southwest France Wines
Singapore Luxury Real Estate: Back to a Buyer's Market
Sail The Seven Seas With Ease In The Oyster 625 Bandido
The Montblanc Meisterstück Is On Point
The Winning Wines of the 2015 En Primeur Campaign
Say Hello To The iPad Pro
See the complete list
Featured Photo Gallery
See the complete list